Tech Company Financing Transactions
Medincell Funding Round
On 11/24/2025, Medincell landed $3 million in funding from Bill & Melinda Gates Foundation.
Transaction Overview
Company Name
Announced On
11/24/2025
Transaction Type
Debt
Amount
$3,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Funding support from the foundation enables Medincell to advance its 3-month active subcutaneous formulation of ivermectin toward a first-in-human trial - a critical step in evaluating its safety and pharmacokinetics, and progressing toward future large-scale field studies to assess its efficacy and potential impact on malaria transmission.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Montpellier, Undisclosed
France
Montpellier, Undisclosed
France
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christophe Douat
Browse more venture capital transactions:
Prev: 11/24/2025: Momentic venture capital transaction
Next: 11/24/2025: Autonomy plc venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs